Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (250 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | UTI - Healthcare Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹127.84 |
| 12 Apr 2015 | ₹221.24 |
| 31 May 2016 | ₹187.99 |
| 19 Jul 2017 | ₹191.16 |
| 07 Sep 2018 | ₹213.33 |
| 27 Oct 2019 | ₹179.57 |
| 15 Dec 2020 | ₹312.31 |
| 03 Feb 2022 | ₹367.16 |
| 25 Mar 2023 | ₹325.57 |
| 12 May 2024 | ₹516.23 |
| 01 Jul 2025 | ₹673.10 |
| 20 Aug 2026 | ₹811.93 |
| Metric | UTI · Direct · IDCW NAV ₹299.44 Very High risk ★★★★★ | Category median Sectoral/ Thematic · 250 funds |
|---|---|---|
| +16.36% | +5.11% | |
| +24.26% | +13.02% | |
| +16.80% | +11.14% | |
| +14.94% | +12.26% | |
| +16.61% | +11.82% | |
| +22.60% | — | |
| +14.85% | +14.62% | |
| +13.85% | +12.95% | |
| +13.69% | +13.24% | |
| Risk | ||
| 13.41% | 15.88% | |
| 1.32 | 0.35 | |
| 1.88 | 0.47 | |
| -27.10% | -25.18% | |
| Nifty 500 | — | |
| +12.68% | +1.40% | |
| 0.77 | 0.98 | |
| 118.3% | 101.5% | |
| 55.7% | 97.0% | |
| 1.27% | 1.14% | |
| ₹1,181Cr | ₹1,162Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 45% | 45% | |
| Kamal Gada | — | |
| 02 Jan 2013 | — | |
| 44 | — | |
| 42.6% | — | |
| 2.9% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.